

Special Issue

The Impact of Comorbidities on Sarcoidosis

Message from the Guest Editor

Sarcoidosis is an uncommon disorder characterized by the presence of noncaseating and non-necrotizing granulomas involving all organs almost ubiquitously, although some, such as the lungs, are more affected. Clinical manifestations are often dominated by lung impairment, but the picture varies depending on the site mainly involved, and nonspecific symptoms can dominate. Some disorders often mimic sarcoidosis; the histopathological features and pathophysiology can overlap and the impact of comorbidities is largely unknown. A comorbidity can be defined as a medical condition which occurs simultaneously with (correlated or not) another and could influence the patient's outcome. The molecular mechanisms and pathophysiology of this interaction are the current object of study. The aim of this Special Issue is to report on the most recent advances regarding the impact of comorbidities on sarcoidosis. Both translational research articles and reviews are welcomed, as well as commentaries concerning recent research evidence.

- sarcoidosis
- comorbidity
- genetics
- molecular mechanisms

Guest Editor

Dr. Claudio Tana

COVID-19 Medicine Unit and Geriatrics Clinic, S.S. Annunziata Hospital of Chieti, 66100 Chieti, Italy

Deadline for manuscript submissions

closed (30 November 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/120967

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).